SEATTLE--(BUSINESS WIRE)--ZymoGenetics, Inc. (NASDAQ:ZGEN) today presented interim results from a Phase 1 clinical trial of Interleukin 21 (IL-21) in combination with Rituxan® (rituximab) in patients with relapsed low-grade B Cell lymphoma at the American Society of Hematology (ASH) 2007 Annual Meeting. The Phase 1 study is part of a larger clinical program examining the use of IL-21 both as a single agent and in combination with approved cancer therapeutics.
